Christopher Powala
2016
In 2016, Christopher Powala earned a total compensation of $2.2M as Chief Operating Officer at Aclaris Therapeutics, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $120,750 |
|---|---|
| Option Awards | $1,397,760 |
| Salary | $345,000 |
| Stock Awards | $300,768 |
| Other | $11,717 |
| Total | $2,175,995 |
Powala received $1.4M in option awards, accounting for 64% of the total pay in 2016.
Powala also received $120.8K in non-equity incentive plan, $345K in salary, $300.8K in stock awards and $11.7K in other compensation.
Rankings
In 2016, Christopher Powala's compensation ranked 4,507th out of 14,075 executives tracked by ExecPay. In other words, Powala earned more than 68.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,507 out of 14,075 | 68th |
Division Manufacturing | 1,597 out of 5,489 | 71st |
Major group Chemicals And Allied Products | 492 out of 1,895 | 74th |
Industry group Drugs | 363 out of 1,538 | 76th |
Industry Pharmaceutical Preparations | 286 out of 1,176 | 76th |
Source: SEC filing on April 21, 2017.
Powala's colleagues
We found two more compensation records of executives who worked with Christopher Powala at Aclaris Therapeutics in 2016.